May be useful in the assessment of acute exposure.
Quantitative Inductively Coupled Plasma-Mass Spectrometry
Diet, medication, and nutritional supplements may introduce interfering substances. Patients should be encouraged to discontinue nutritional supplements, vitamins, minerals, and non-essential over-the-counter medications (upon the advice of their physician). High concentrations of iodine may interfere with elemental testing. Collection from patients receiving iodinated or gadolinium-based contrast media must be avoided for a minimum of 72 hours post-exposure. Collection from patients with impaired kidney function should be avoided for a minimum of 14 days post contrast media exposure.
24 Hour Urine. Refrigerate during collection. Specimen must be collected in a plastic container. Also acceptable: Random Urine.
Transfer an 8 mL aliquot from a well-mixed collection to ARUP Trace Element-Free Transport Tubes (ARUP supply #43116) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. (Min: 1 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Specimens collected within 72 hours after administration of iodinated or gadolinium-based contrast media. Acid preserved urine. Specimens transported in containers other than specified. Specimens contaminated with blood or fecal material.
Record total volume and collection time interval on transport tube and on test request form.
Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 1 year
|Cobalt, Urine - per volume||Effective August 21, 2017
|Cobalt, Urine - per 24h||Effective August 21, 2017
|0020473||Creatinine, Urine - per 24h||
|Cobalt, Urine - ratio to CRT||Effective August 21, 2017
0.0-4.2 (µg/g CRT)
Cobalt urine levels can be used to monitor acute exposure as the reported half-life of cobalt is on the order of several days. Urine cobalt levels generally do not exceed 1.0 µg/L in the general population and are rarely used in the management of chronic exposure. Symptoms associated with cobalt toxicity vary based upon route of exposure and may include cardiomyopathy, allergic dermatitis, pulmonary fibrosis, cough and dyspnea.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0020207||Creatinine, Urine - per volume||2161-8|
|0020208||Creatinine, Urine - per 24h||2162-6|
|0025033||Cobalt, Urine - per volume||21208-4|
|0025034||Cobalt, Urine - per 24h||29916-4|
|0025035||Cobalt, Urine - ratio to CRT||29934-7|
- Co Urine, Normalized
- Cobalt, 24-Hour Urine
- Cobalt/Creatinine, Random, Urine
- Normalized Urine Co
- Normalized Urine Cobalt
- Urine cobalt concentration